Sort   by:  
 Page size 
UnknownEffect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.

Importance

The evidence for benefit of convalescent plasma for critically ill patients with COVID-19 is inconclusive.

Objective

To determine whether convalescent plasma would improve outcomes for critically ill adults with COVID-19.

Design, setting, and participants

The ongoing...
S-EPMC8491132 | biostudies-literature
UnknownEvaluation of a quality improvement intervention to reduce anastomotic leak following right colectomy (EAGLE): pragmatic, batched stepped-wedge, cluster-randomized trial in 64 countries.

Background

Anastomotic leak affects 8 per cent of patients after right colectomy with a 10-fold increased risk of postoperative death. The EAGLE study aimed to develop and test whether an international, standardized quality improvement intervention could reduce anastomotic leaks.

Methods<...

S-EPMC10771257 | biostudies-literature
UnknownEvaluation of appendicitis risk prediction models in adults with suspected appendicitis.

Background

Appendicitis is the most common general surgical emergency worldwide, but its diagnosis remains challenging. The aim of this study was to determine whether existing risk prediction models can reliably identify patients presenting to hospital in the UK with acute right iliac fossa ...
S-EPMC6972511 | biostudies-literature
UnknownThe impact of surgical delay on resectability of colorectal cancer: An international prospective cohort study.

Aim

The SARS-CoV-2 pandemic has provided a unique opportunity to explore the impact of surgical delays on cancer resectability. This study aimed to compare resectability for colorectal cancer patients undergoing delayed versus non-delayed surgery.

Methods

This was an international pro...
S-EPMC9322431 | biostudies-literature
UnknownEffects of medical therapies on retinopathy progression in type 2 diabetes.

Background

We investigated whether intensive glycemic control, combination therapy for dyslipidemia, and intensive blood-pressure control would limit the progression of diabetic retinopathy in persons with type 2 diabetes. Previous data suggest that these systemic factors may be important in...
S-EPMC4026164 | biostudies-literature
UnknownEffects of intensive blood-pressure control in type 2 diabetes mellitus.

Background

There is no evidence from randomized trials to support a strategy of lowering systolic blood pressure below 135 to 140 mm Hg in persons with type 2 diabetes mellitus. We investigated whether therapy targeting normal systolic pressure (i.e., <120 mm Hg) reduces major cardiovascular...
S-EPMC4123215 | biostudies-literature
UnknownEffect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.

Background

Hyperglycaemia is associated with increased risk of cardiovascular complications in people with type 2 diabetes. We investigated whether reduction of blood glucose concentration decreases the rate of microvascular complications in people with type 2 diabetes.

Methods

ACCORD...
S-EPMC4123233 | biostudies-literature
UnknownEffects of combination lipid therapy in type 2 diabetes mellitus.

Background

We investigated whether combination therapy with a statin plus a fibrate, as compared with statin monotherapy, would reduce the risk of cardiovascular disease in patients with type 2 diabetes mellitus who were at high risk for cardiovascular disease.

Methods

We randomly ass...
S-EPMC2879499 | biostudies-literature
UnknownEffects of intensive glucose lowering in type 2 diabetes.

Background

Epidemiologic studies have shown a relationship between glycated hemoglobin levels and cardiovascular events in patients with type 2 diabetes. We investigated whether intensive therapy to target normal glycated hemoglobin levels would reduce cardiovascular events in patients with ...
S-EPMC4551392 | biostudies-literature
UnknownEfficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.

Background

Degludec is an ultralong-acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-to-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients ...
S-EPMC5731244 | biostudies-literature
Sort   by:  
 Page size